Pliant Therapeutics, Inc.
PLRX
$1.07
-$0.01-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.19M | 7.69M | 10.33M | 13.39M | 15.50M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.77M | 21.08M | 28.17M | 45.59M | 58.94M |
| Operating Income | -21.77M | -21.08M | -28.17M | -45.59M | -58.94M |
| Income Before Tax | -20.04M | -23.58M | -26.30M | -43.30M | -56.17M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -20.04M | -23.58M | -26.30M | -43.30M | -56.17M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.04M | -23.58M | -26.30M | -43.30M | -56.17M |
| EBIT | -21.77M | -21.08M | -28.17M | -45.59M | -58.94M |
| EBITDA | -21.51M | -20.71M | -27.73M | -45.15M | -58.49M |
| EPS Basic | -0.32 | -0.38 | -0.43 | -0.71 | -0.92 |
| Normalized Basic EPS | -0.20 | -0.20 | -0.27 | -0.44 | -0.57 |
| EPS Diluted | -0.32 | -0.38 | -0.43 | -0.71 | -0.92 |
| Normalized Diluted EPS | -0.20 | -0.20 | -0.27 | -0.44 | -0.57 |
| Average Basic Shares Outstanding | 61.80M | 61.45M | 61.41M | 61.39M | 61.22M |
| Average Diluted Shares Outstanding | 61.80M | 61.45M | 61.41M | 61.39M | 61.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |